ANIP Ani Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP

Price (delayed)

$38.38

Market cap

$671.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.05

Enterprise value

$905.09M

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
The gross profit has surged by 54% year-on-year and by 21% since the previous quarter
Ani Pharmaceuticals's revenue has increased by 46% YoY and by 12% from the previous quarter
Ani Pharmaceuticals's net income has increased by 29% QoQ but it has decreased by 12% YoY
ANIP's quick ratio is down by 16% year-on-year and by 11% since the previous quarter
The company's equity fell by 6% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com/
Peers: JAZZ TEVA PFE INFI

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
17.5M
Market cap
$671.81M
Enterprise value
$905.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.14
Price to sales (P/S)
1.97
EV/EBIT
N/A
EV/EBITDA
36.15
EV/Sales
2.86
Earnings
Revenue
$316.39M
EBIT
-$34.61M
EBITDA
$25.04M
Free cash flow
-$39.33M
Per share
EPS
-$3.05
Free cash flow per share
-$2.42
Book value per share
$17.96
Revenue per share
$19.46
TBVPS
$29.53
Balance sheet
Total assets
$760.09M
Total liabilities
$421.55M
Debt
$286.52M
Equity
$313.69M
Working capital
$244.82M
Liquidity
Debt to equity
0.91
Current ratio
3.46
Quick ratio
2.2
Net debt/EBITDA
9.32
Margins
EBITDA margin
7.9%
Gross margin
56.1%
Net margin
-15.1%
Operating margin
-9.8%
Efficiency
Return on assets
-6.6%
Return on equity
-15.7%
Return on invested capital
-5.9%
Return on capital employed
-5.2%
Return on sales
-10.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
2.05%
1 week
-2.47%
1 month
-8.25%
1 year
37.22%
YTD
-4.6%
QTD
-4.6%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$316.39M
Gross profit
$177.6M
Operating income
-$30.86M
Net income
-$47.9M
Gross margin
56.1%
Net margin
-15.1%
ANIP's operating margin has surged by 54% since the previous quarter and by 51% year-on-year
The gross profit has surged by 54% year-on-year and by 21% since the previous quarter
The company's operating income rose by 49% QoQ and by 29% YoY
Ani Pharmaceuticals's revenue has increased by 46% YoY and by 12% from the previous quarter

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.14
P/S
1.97
EV/EBIT
N/A
EV/EBITDA
36.15
EV/Sales
2.86
The company's EPS rose by 34% QoQ and by 10% YoY
The P/B is 21% below the 5-year quarterly average of 2.7 but 19% above the last 4 quarters average of 1.8
The company's equity fell by 6% YoY
Ani Pharmaceuticals's revenue has increased by 46% YoY and by 12% from the previous quarter
The price to sales (P/S) is 27% lower than the 5-year quarterly average of 2.7

Efficiency

How efficient is Ani Pharmaceuticals business performance
The company's return on sales has surged by 51% QoQ and by 47% YoY
Ani Pharmaceuticals's ROIC has increased by 46% from the previous quarter and by 44% YoY
The ROA has grown by 28% from the previous quarter and by 15% YoY
The return on equity has grown by 27% since the previous quarter and by 16% year-on-year

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 80% more than its total liabilities
ANIP's quick ratio is down by 16% year-on-year and by 11% since the previous quarter
The company's current ratio fell by 9% QoQ and by 6% YoY
The debt is 9% lower than the equity
The debt to equity has increased by 6% YoY
The company's equity fell by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.